DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Roniciclib is an investigational drug.
There have been 7 clinical trials for Roniciclib. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2014.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Bayer, Dana-Farber Cancer Institute, and Yonsei University.
There are five US patents protecting this investigational drug and eighty-nine international patents.
Recent Clinical Trials for Roniciclib
|BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors||Bayer||Phase 2|
|BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors||Dana-Farber Cancer Institute||Phase 2|
|An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)||Yonsei University||Phase 1/Phase 2|
Top disease conditions for Roniciclib
Top clinical trial sponsors for Roniciclib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Roniciclib||See Pricing||FAP-activated therapeutic agents, and uses related thereto||BACH BIOSCIENCES, LLC (Cambridge, MA)||See Pricing|
|Roniciclib||See Pricing||Human papilloma virus as predictor of cancer prognosis||Foundation Medicine, Inc. (Cambridge, MA) UCL Business PLC (London, GB)||See Pricing|
|Roniciclib||See Pricing||Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine||Bayer Intellectual Property GmbH (Monheim, DE)||See Pricing|
|Roniciclib||See Pricing||Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation||Bayer Intellectual Property GmbH (Monheim, DE)||See Pricing|
|Roniciclib||See Pricing||Human papilloma virus as predictor of cancer prognosis||FOUNDATION MEDICINE, INC. (Cambridge, MA) UCL Business PLC (London, GB)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Roniciclib||European Patent Office||3154594||2034-06-13||See Pricing|
|Roniciclib||World Intellectual Property Organization (WIPO)||2015192123||2034-06-13||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|